Lilly Zyprexa Rebound Plan Begins With Approval For Bipolar Maintenance
Executive Summary
Lilly hopes that approval of Zyprexa for use as bipolar maintenance therapy will help fuel a rebound in prescriptions for the atypical antipsychotic, CEO Sidney Taurel said Jan. 13 at the J.P. Morgan health care conference in San Francisco